Clinical Trial Update: FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

An early-phase (Phase I/IIa) clinical trial evaluating the safety of TUM012 to minimize ischemia-reperfusion injury in kidney transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Kidney Transplantation

Drugs mentioned

• TUM012

Snippet

Sponsor: iCoat Medical AB | Conditions: Ischemia-reperfusion Injury, Kidney Transplant; Complications | Phase 1, Phase 2 | Status: COMPLETED